| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8242811 | International Journal of Radiation Oncology*Biology*Physics | 2007 | 10 Pages |
Abstract
Conclusion: Biweekly gemcitabine (40 mg/m2) concurrently with RT (52.5 Gy in 30 fractions of 1.75 Gy) with or without induction gemcitabine is safe and tolerable and shows efficacy in patients with LA and resected pancreatic cancer.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Anthony M.D., Ph.D., James M.B., Amit M.D., Steven M.D., Bernard M.B., Martha R.N., Gregory R. M.Sc., David M.D., Shun M.D., Carol M.D., Christine M.D., Ph.D., Malcolm M.D.,